# **BMJ Open** Validating the recording of exacerbations of asthma in electronic health records: a systematic review protocol

Elizabeth Moore 💿, Zakariah Z Gassasse 💿, Jennifer K Quint 💿

### ABSTRACT

Introduction Asthma exacerbations or 'attacks' can

vary in severity from mild worsening of symptoms to

life-threatening changes that require urgent hospital

care. Understanding these exacerbations is crucial to

improving treatment and support for patients. Electronic

health records (EHR) using anonymised data from people

with asthma in primary and secondary care can be used

to understand exacerbations and outcomes. However,

previous studies found significant heterogeneity in the

definitions of asthma exacerbations in EHR will lead to

Methods and analysis Medline and Embase will

be searched for the key concepts relating to asthma

algorithms used to define asthma exacerbations. Validating

more robust and comparable evidence in future research.

exacerbations, EHR and validation. All studies that validate

exacerbations of asthma in EHR and administrative claims

databases published before 30 May 2024 and written in English will be considered. Validated algorithms for asthma

exacerbations or attacks must be compared against a reference or gold standard definition, and a measure

of validity must be included. Articles will be screened

for inclusion by two independent reviewers with any

disagreements resolved by consensus or arbitration by a

third reviewer. Study details will be extracted, and the risk

of bias will be assessed using a QUADAS-2 tailored to this

Ethics & dissemination No ethical approval is required

Results will be disseminated in a peer-reviewed journal with the aim of being used in future research to help

PROSPERO registration number CRD42024545081

as this is a review of previously published literature.

To cite: Moore E, Gassasse ZZ, Quint JK. Validating the recording of exacerbations of asthma in electronic health records: a systematic review protocol. BMJ Open 2024;14:e088849. doi:10.1136/ bmjopen-2024-088849

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-088849).

Received 16 May 2024 Accepted 22 October 2024

Check for updates

review.

C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BM.J.

School of Public Health, Imperial College London, London, UK

**Correspondence to** Elizabeth Moore: liz.moore@imperial.ac.uk INTRODUCTION Asthma is a common chronic lung disease

identify asthma exacerbation in EHR.

that affects people of all ages and is characterised by inflammation and muscle tightening around the airways resulting in symptoms such as cough, wheeze, shortness of breath and chest tightness.<sup>1</sup> Exacerbations of asthma are defined in the Global Initiative for Asthma as events that involve a progressive increase in symptoms and a progressive decrease in lung function that are 'sufficient

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- $\Rightarrow$  This review will report the methods and findings of studies that validate definitions of asthma exacerbations in electronic health records (EHR).
- ⇒ Medical databases will be searched for the key concepts relating to asthma exacerbations. EHR and validation.
- $\Rightarrow$  Study details will be extracted, and the risk of bias will be assessed using a QUADAS-2 tailored to this review.
- $\Rightarrow$  Validated algorithms for asthma exacerbations or attacks will be compared against a reference or gold standard definition, and measures of validity will be reported.

to require a change in treatment'.<sup>2</sup> Exacerbations of asthma or 'attacks' can vary in erbations of asthma or 'attacks' can vary in a severity from mild worsening of symptoms a that only require the use of inhalers to severe, life-threatening changes that require urgent treatment in hospital.<sup>3</sup> Severe asthma attacks have accounted for over 90,000 UK hospital ≥ admissions per annum.<sup>4</sup> There is convincing the evidence of heterogeneity in acute asthma, as there is in stable asthma, and validating **9**. criteria to define asthma attacks may improve treatment and outcomes.5

Electronic health records (EHR) can be used in observational studies to understand diseases, treatments and outcomes. Researchers can access anonymised data collected from primary and secondary care, providing them with large study samples that **&** are often more generalisable to wider populations. Information regarding diagnoses and clinical events is stored in EHR as clinical codes and/or associated values. Health records can be retrieved using coding (either a single code or an algorithm consisting of multiple codes or associated values), and researchers can apply additional restrictions if desired (eg, age or exclusion of other diseases). Some authors have also used natural language

and

Protected by copyright, including for uses related to text

processing and machine learning techniques to identify asthma diagnoses in large databases through automated algorithm generation.<sup>6–8</sup> This methodology follows a set of rules that may make codelist generation 'Blackbox' and are not always clear.

Previous studies have shown the importance of validating definitions in EHR to ensure robust, comparable study findings.<sup>9</sup> Comparing EHR data with a gold standard is the most common method to assess validity of algorithms, and these gold standards can include paper records, verification by a treating physician or through patient questionnaires, data review and alternative data sources such as linkable datasets.<sup>10</sup>

Previous studies have sought to examine the validity of asthma diagnoses in EHR. A scoping review by Al Sallakh *et al*<sup>11</sup> found a lack of consensus in approaches to defining asthma or assessing asthma outcomes in EHR with significant heterogeneity in the algorithms used to define exacerbations of asthma. It highlighted the fundamental need to reach a consensus on the definitions of asthma exacerbations in EHR. Nissen et al<sup>12</sup> carried out a systematic review of studies looking at asthma recording in EHR. Their review found that definitions and methods of asthma diagnosis validation vary widely across different EHR databases, and asthma symptoms present differently depending on the setting (eg, primary care, secondary care and urgent care). Sharifi *et al*<sup>13</sup> conducted a systematic review of validated methods to capture acute bronchospasm, which is a hallmark of asthma, using administrative or claims data. They found a paucity of studies using rigorous methods to validate algorithms for the identification of acute asthma or bronchospasms in general populations, with only three studies reporting any validation, and all were among paediatric populations. A similar review to validate acute exacerbations of chronic obstructive pulmonary disease (COPD) is currently being undertaken<sup>14</sup>; however, to our knowledge, there has not been another systematic review of studies that validate definitions of asthma exacerbations in EHR.

#### **OBJECTIVE**

This review will report the methods and findings of studies that validate definitions of asthma exacerbations in EHR. The target population are people with asthma, the intervention measured (index test) will be the detection algorithms for exacerbations of asthma, the comparison will be the reference standard used to confirm exacerbations of asthma and the outcome will be the validity of the detection algorithms. Studies will be included from any country, in any EHR database and using any clinical coding. In our review, we will specifically explore the following:

- ▶ The database and type of EHR used.
- ► The algorithm (codelists) used to detect asthma exacerbations.
- ► The reference standard used to validate asthma exacerbations.

 The estimated validity of the detection algorithm for asthma exacerbations.

### **METHODS AND ANALYSIS**

Medline and Embase will be searched via Ovid for the key concepts of 'asthma exacerbations', 'electronic health records' or 'administrative claims database' and 'validation'. The full search strategy is described in online supplemental file 1. In order to detect the validation terms, we will use the same search strategy used by Stone *et al*<sup>14</sup> in a similar review validating COPD exacerbations in EHR. This was based on search methodology by Benchimol *et al*<sup>15</sup> and strategies used in similar reviews of validation studies in EHR databases.<sup>12 16–18</sup>

### **Inclusion criteria**

- Studies written in English and published before 30 May 2024 will be considered.
- ► Data must be from an EHR or administrative claims database.
- ► Adult and paediatric studies will be included and where appropriate, different treatment regimens and outcomes will be taken into consideration.
- Validated algorithms for asthma exacerbations or attacks must be compared against a reference or gold standard definition (eg, records review by treating physicians).
- ► A measure of validity must be included (eg, positive predictive value (PPV), negative predictive value (NPV), and sensitivity and specificity) or can be calculable from information provided in the study.

#### **Exclusion criteria**

Studies will be excluded if they only look at asthma diagnosis rather than asthma attacks/exacerbations.

#### DATA MANAGEMENT AND SYNTHESIS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist by Moher et al<sup>19</sup> will be followed, and the PRISMA flow diagram for this protocol is shown in figure 1 in online supplemental file 2. Articles found in the literature search will be stored on EndNote 21 (Clarivate Analytics, Philadelphia, Pennsylvania, USA), and duplicates will be removed. All unique articles will be screened by two reviewers, and if the inclusion criteria are met, a full text review will be carried out. Any disagreement regarding the inclusion/exclusion of **g** articles will be resolved by consensus or arbitration by a third reviewer, and reasons for exclusion from the review will be recorded. Both reviewers will read the full texts and will independently extract study details. Data will be tabulated and stored in Microsoft Excel (Microsoft, Redmond, Washington, USA), and the following information from each study will be recorded:

- Study details (including title, first author and year of publication).
- ► Study aim/research question.

BMJ Open: first published as 10.1136/bmjopen-2024-088849 on 12 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- ► EHR database used.
- ▶ Population (location, time period).
- Type of algorithm(s) used to detect asthma exacerbations (eg, clinical coding scheme).
- Reference/gold standard used to compare the algorithm(s) against.
- ► Measure(s) of validity (eg, PPV and NPV).
- Results of validated measures.
- Prevalence of asthma exacerbations.
- Information to calculate validity (where available: true positives, false positives, true negatives, false negatives).

The primary outcome measure sought will be the validity of the asthma exacerbation detection algorithm.

Risk of bias (ROB) will be assessed using a quality assessment tool for diagnostic accuracy studies known as QUADAS-2.<sup>20</sup> We will tailor the QUADAS-2 to this specific review as done in other similar reviews<sup>1421</sup> using a recommended reporting checklist by Benchimol *et al*<sup>15</sup> for use in validation studies of health administrative data. Our tailored QUADAS-2 can be found in online supplemental file 3. If there are multiple validations reported, we will complete a ROB assessment for each validation. Results will be presented in the text and in tables to summarise study details, the algorithms used to validate exacerbations of asthma in EHR, the reference standard used to validate the algorithm, the validity of the algorithms and the ROB in the studies.

This review will identify and assess the best algorithm to use in future asthma research when using particular clinical terminology by comparing the methods and results of the validated algorithms from similar databases that use the same clinical coding. If studies are sufficiently comparable in that they have been carried out in similar populations and using similar reference standards, we will use bivariate random effects regression to calculate the summary measure of sensitivity and specificity<sup>22</sup> or PPV and NPV<sup>23</sup> (where no sensitivity and specificity values are provided), as described in the protocol for COPD exacerbations by Stone *et al.*<sup>14</sup>

# PATIENT AND PUBLIC INVOLVEMENT

Patients and the public will be involved in determining our final consensus algorithm as part of the larger project but have not been included at this stage as we are collating what already exists in the literature.

# **ETHICS AND DISSEMINATION**

This is a review of previously published literature that is publicly available and therefore does not require ethical approval. This protocol has been registered on PROS-PERO: International Prospective Register of Systematic Reviews (registration number: CRD42024545081). The findings of the review will be disseminated via presentation at relevant scientific conferences and publication in a peer-reviewed journal. The BMJ Open instructions for reviewers of study protocols can be found in online supplemental file 4.

#### X Zakariah Z Gassasse @zgassasse

**Contributors** JKQ and EM developed the research question. EM developed the search strategy with input from ZZG and JKQ. EM drafted the manuscript. EM, JKQ and ZZG contributed to production of the final manuscript. All authors read, commented on and approved the protocol and final manuscript. EM acted as a guarantor.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** The author JKQ has been supported by institutional research grants from the Medical Research Council, NIHR, Health Data Research, GSK, BI, AZ, Insmed and Sanofi and received personal fees for advisory board participation, consultancy or speaking fees from GlaxoSmithKline, Chiesi and AstraZeneca.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

### ORCID iDs

Elizabeth Moore http://orcid.org/0000-0003-1660-7598 Zakariah Z Gassasse http://orcid.org/0000-0003-3079-1563 Jennifer K Quint http://orcid.org/0000-0003-0149-4869

# REFERENCES

- 1 World Health Organization. Asthma key facts. 2023. Available: https://www.who.int/news-room/fact-sheets/detail/asthma
  - 2 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2019.
- 3 Jin J. Asthma Attacks. JAMA 2016;315:832.
- 4 Mukherjee M, Stoddart A, Gupta RP, *et al.* The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. *BMC Med* 2016;14:113.
- 5 Martin MJ, Beasley R, Harrison TW. Towards a personalised treatment approach for asthma attacks. *Thorax* 2020;75:1119–29.
- 6 Sanders DL, Gregg W, Aronsky D. Identifying asthma exacerbations in a pediatric emergency department: a feasibility study. *Int J Med Inform* 2007;76:557–64.
- 7 Afzal Z, Engelkes M, Verhamme KMC, et al. Automatic generation of case-detection algorithms to identify children with asthma from large electronic health record databases. *Pharmacoepidemiol Drug Saf* 2013;22:826–33.
- 8 Wu ST, Juhn YJ, Sohn S, et al. Patient-level temporal aggregation for text-based asthma status ascertainment. J Am Med Inform Assoc 2014;21:876–84.
- 9 Whittaker H, Rothnie KJ, Quint JK. Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records. *PLoS ONE* 2023;18:e0292876.
- 10 Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. *J Am Med Inform Assoc* 2013;20:144–51.

# **Open access**

- 11 Al Sallakh MA, Vasileiou E, Rodgers SE, *et al.* Defining asthma and assessing asthma outcomes using electronic health record data: a systematic scoping review. *Eur Respir J* 2017;49:1700204.
- 12 Nissen F, Quint JK, Wilkinson S, et al. Validation of asthma recording in electronic health records: a systematic review. *Clin Epidemiol* 2017;9:643–56.
- 13 Sharifi M, Krishanswami S, McPheeters ML. A systematic review of validated methods to capture acute bronchospasm using administrative or claims data. *Vaccine (Auckl)* 2013;31 Suppl 10:K12–20.
- 14 Stone P, Sood N, Feary J, et al. Validation of acute exacerbation of chronic obstructive pulmonary disease (COPD) recording in electronic health records: a systematic review protocol. BMJ Open 2020;10:e032467.
- 15 Benchimol El, Manuel DG, To T, *et al.* Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. *J Clin Epidemiol* 2011;64:821–9.
- 16 Jayatunga W, Stone P, Aldridge RW, *et al.* Code sets for respiratory symptoms in electronic health records research: a systematic review protocol. *BMJ Open* 2019;9:e025965.

- 17 Leong A, Dasgupta K, Bernatsky S, et al. Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. PLoS ONE 2013;8:e75256.
- 18 Shiff NJ, Jama S, Boden C, et al. Validation of administrative health data for the pediatric population: a scoping review. BMC Health Serv Res 2014;14:236.
- 19 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
- 20 Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
- 21 Fawkner-Corbett D, Hayward G, Alkhmees M, et al. Diagnostic accuracy of blood tests of inflammation in paediatric appendicitis: a systematic review and meta-analysis. BMJ Open 2022;12:e056854.
- 22 Reitsma JB, Glas AS, Rutjes AWS, *et al.* Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol* 2005;58:982–90.
- 23 Leeflang MMG, Deeks JJ, Rutjes AWS, *et al.* Bivariate meta-analysis of predictive values of diagnostic tests can be an alternative to bivariate meta-analysis of sensitivity and specificity. *J Clin Epidemiol* 2012;65:1088–97.